With a robust collection of 500,000 individuals, the UK Biobank will succeed in its mission to study the determinants of disease through genetics and proteomics combined with extensive electronic health records and ongoing assessments What the UK Biobank is and its current status The UK Biobank (abbreviated UKB or UKBB) began in 2006 as a … Read more
Cardea Bio Inc. and Nanosens Innovations Inc., Keck Graduate Institute and UC Berkeley detect two deleted DMD exons in 15 minutes down to 1.7 fM sensitivity We are currently living in an exciting time in molecular diagnostics, as the fields of chemical fluorescence, optics, electronics, microfluidics, biochemistry, genomics and nanofabrication intersect and produce surprising synergies. … Read more
An unusual presentation by a recently-retired NASA scientist Dr. John Charles shares an unusual and highly entertaining presentation entitled “From here to Mars: How the Twins Study and the year-long ISS mission have moved us closer to the red planet” The agenda of AGBT runs a wide range of topics, from the highly specific on … Read more
At #AGBT19 there is a palpable movement from dissociated single cells to single cells in situ Every year at the Advances of Genome Biology and Technology you can see what the future holds. When long-read sequencing was introduced in 2011, people here at AGBT19 are still talking about that Pacific Biosciences fireworks display on the … Read more
Here at the American Society for Human Genetics (#ASHG18) it has been several years since I’ve attended. The exhibit hall is as large as ever, plenty of new firms in DTC (Direct To Consumer) genomics, bioinformatics, and other technical feats are out in full-force. The new Singlera website is now live. What has been fun … Read more
Announcing a big move for Dale affecting his family, his employer, his colleagues, and his friends Note: This article originally appeared on LinkedIn. The magic wand of early detection Several years ago at a meeting with sales management, someone asked a provocative question: “If you had a magic wand, what would you ask for?” If … Read more
Can a graphene biosensor company like Cardea Biosciences play a role in making P4 medicine (predictive, preventive, personalized and participatory medicine) a reality? Lee Hood’s vision for P4 medicine It was about six years ago I attended a Personalized Healthcare conference at Virginia Commonwealth University in Richmond Virginia, where Leroy Hood of the Institute of … Read more
Now that another year has passed it is great to see the NanoString Digital Spatial profiling microscope near its commercial launch. The platform will be in early access to select customers in the fourth quarter of 2018, and full commercial launch in the first half of 2019. For those interested in accessing the technology, they … Read more
John Iafrede (Massachusetts General Hospital, MA) “There is a tidal wave of cell-free approaches; little performance testing; and the big question is who is going to pay for it.” This year’s Assocation for Molecular Pathology was held in Salt Lake City, Utah from November 15-18, 2017. (You can find the 2017 program and abstract here.) … Read more
While at the Association for Molecular Pathology in Salt Lake City Utah, I was able to interview Gang Song CEO of Pillar Biosciences to ask him about the challenges in the clinical laboratory that Pillar is tackling, about the basics of SLIMamp technology, and recent news. Check it out! #AMP2017
With over 2000 clinical laboratory professionals in molecular diagnostics and pathology, plenty of technology and offerings on display. This year the Association for Molecular Pathology takes place in Salt Lake City Utah, and promises an abundance of new technology as well as the new accompanying science around diagnostic testing. Since this is a molecular pathology … Read more
What happens when commercial interests do not align? Over a decade ago in 2002 when Novartis announced it was moving its global headquarters to Boston MA, it was viewed at the time that the United State’s pharmaceutical market was the most robust and attractive, and it made sense for Novartis to have a major presence … Read more